Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)
Alexion Europe SAS
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
1 trial -
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Baxalta Innovations GmbH
Hemophilia A
1 trial -
Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Takeda
Hemophilia A
1 trial -
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
BAX 326 (Recombinant factor IX)
Takeda
Hemophilia B
1 trial -
Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Trumenba suspension for injection in pre-filled syringe Meningococcal group B vaccine (recombinant, adsorbed)
Pari Pharma GmbH
Asplenia
1 trial -
Beyfortus 100 mg solution for injection in pre-filled syringe, Beyfortus 50 mg solution for injection in pre-filled syringe, Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)
Fondazione Telethon ETS
Respiratory Syncytial Virus (RSV)
1 trial -
Coagulation Factor VIIa (Recombinant)
Laboratoire HRA Pharma
Hemophilia
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Merck Sharp and Dohme
9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
The George Institute
Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed), SODIUM CHLORIDE
Pari Pharma GmbH
External Genital Warts (EGW)
1 trial -
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Norovirus Infections
1 trial -
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Sanofi Pasteur
Dengue Fever
1 trial -
PEGylated Recombinant Factor VIII
Takeda
Hemophilia A
2 trials -
PEGylated Recombinant factor VIII (rFVIII)
Takeda
Hemophilia A
1 trial -
RECOMBINANT ADAMTS13 (rADAMTS13), RECOMBINANT ADAMTS13 (rADAMTS13)
Baxalta Innovations GmbH
Congenital Thrombotic thrombocytopenic purpura (cTTP)
1 trial -
Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV InfectioN
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Takeda
Hemophilia A
1 trial -
Recombinant Factor VIII (BAY81-8973)
Bayer HealthCare AG
Blood Coagulation Disorders
1 trial -
Recombinant Factor VIIa
United Therapeutics Europe Ltd
Burns
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources